The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

MeiraGTx Holdings shares rose 13% in premarket trading on a collaboration with Hologen that will bring in a cash infusion and create a joint venture. Shares were trading around $7.28. The stock is up ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.

MeiraGTx (NASDAQ:MGTX – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, ...

Investing.com -- Shares of MeiraGTx Holdings plc ( Nasdaq: NASDAQ: MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 ...